New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 30, 2014
07:08 EDTINSYInsys backs Q2 revenue view of over $52M, consensus $52.77M
Insys Therapeutics reaffirmed its revenue guidance for Q2 ended June 30. Revenue from sales of Subsys is expected to exceed $52M for the quarter, as compared with $18.5M during 2Q13.
News For INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 15, 2014
07:12 EDTINSYInsys Therapeutics price target raised to $57 from $53 at RBC Capital
Subscribe for More Information
December 9, 2014
07:12 EDTINSYInsys Therapeutics receives FDA orphan drug designation for LEP-ETU
Insys Therapeutics announced that the FDA has granted orphan drug designation to its Liposome Entrapped Paclitaxel Easy to Use, or LEP-ETU, candidate for the treatment of gastric cancer. LEP-ETU is an improved formulation of paclitaxel, a widely used chemotherapeutic agent. Insys acquired LEP-ETU during its merger in 2010 with NeoPharm.
December 8, 2014
10:35 EDTINSYInsys Therapeutics management to meet with Piper Jaffray
Subscribe for More Information
10:00 EDTINSYOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:18 EDTINSYInsys Therapeutics initiated with a Buy at Jefferies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use